AI-enabled drug transactions increasingly turn on more than patents and scientific merit. This article examines data provenance, IP ownership, collaboration terms, and model dependencies that can affect diligence, valuation, and deal readiness.

In AI-enabled drug discovery, enterprise value depends on more than the pipeline. Data ownership, licensing terms, model improvements, and platform dependencies can shape IP strategy, diligence, and commercialization.

AI can accelerate innovation, but it can also introduce synthetic prior art that undermines biotech IP. Explore key risks in operability, public access, and misuse. Learn how to protect your patent filings with expert strategies.